Amgen CFO Griffith to Retire, Dittrich to Succeed in September 2026
AMGN•Amgen CFO Peter Griffith will retire after a six-year tenure and be succeeded by Thomas Dittrich, who takes on the role effective September 1, 2026, with a transition period until January 2027. Dittrich, returning as EVP, brings over 30 years of CFO experience from Galderma, Shire and Sulzer.
1. CFO Transition Timeline
Peter Griffith, who has served as Amgen’s executive vice president and CFO since 2020, will retire effective September 1, 2026, and remain through January 2027 to ensure a smooth handover. Thomas Dittrich will return to Amgen as executive vice president on July 1 and assume full CFO responsibilities on September 1, 2026.
2. Dittrich's Financial Background
Dittrich brings over 30 years of international leadership in finance, including recent service as CFO of Galderma and prior CFO roles at Shire and Sulzer. He previously held senior finance positions at Amgen, equipping him with deep insight into the company’s biopharmaceutical operations and capital allocation strategy.
3. Potential Impact on Amgen
As CFO, Dittrich will oversee all financial operations, building on Griffith’s efforts to strengthen Amgen’s financial foundation and disciplined capital allocation. His appointment aims to maintain continuity in funding R&D and supporting long-term growth initiatives across Amgen’s oncology, inflammation and rare disease portfolios.
